RE:RE:RE:RE:RE:RE:ASCO June 2023Yes, and I'd like to know a lot of the baseline data - especially which cancer/tumor types since that appears to have become more meaningful and some may drop out, prior treatment types (since we know a few clash now), and especially what kind of physical shape many were in. The anecdotes we know of saw some extremely advanced patients and they never proceeded beyond a few doses for whatever reason before dis-enrolling. Trials like this are very difficult and this may shed some light on some of those issues. It's a problem for all these refractory studies though, and some meet their endpoints.